IP Library Granted Patent US 9,119,554
Granted Patent B2
US 9,119,554 · App. 12/949,720 · Granted Sep 1, 2015

Pharma-informatics system

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,119,554
App. No.
12/949,720
Granted
Sep 1, 2015
Kind
B2
Abstract

Compositions, systems and methods that allow for the detection of the actual physical delivery of a pharmaceutical agent to a body are provided. Embodiments of the compositions include an identifier and an active agent. The invention finds use in a variety of different applications, including but not limited to, monitoring of therapeutic regimen compliance, tracking the history of pharmaceutical agents, etc.

Claims (39)

1. An ingestible device comprising:

a support;

circuitry associated with the support;

a first material electrically coupled to the circuitry and associated with the support; and

a second material electrically coupled to the circuitry and associated with the support, wherein the first material is electrically isolated from the second material, wherein the first and second materials are selected to provide a voltage potential difference when in contact with an electrically conductive fluid, and wherein the circuitry is configured to modulate current flow through the electrically conductive fluid to generate an encoded monophasic signal which is conductively transmitted to a remote receiver; and

wherein the circuitry comprises a switch; and

wherein the circuitry is configured such that when the switch is closed, a current is produced between the first material and the second material.

2. The device according to claim 1 , wherein the support comprises a semiconductor.

3. The device according to claim 1 , wherein at least one of the first material and the second material are configured to be consumed and dissolved by the electrically conductive fluid.

4. The device according to claim 3 , wherein the first material comprises a metal is selected from the group consisting of magnesium, zinc, sodium, lithium and iron.

5. The device according to claim 4 , wherein the first material is doped with a non-metal.

6. The device according to claim 1 , wherein the second material is a salt.

7. The device according to claim 6 , wherein the salt is selected from the group consisting of copper salts and iron salts.

8. The device according to claim 1 , wherein the first material is a metal and the second material is a salt.

9. The device according to claim 1 , wherein the device is smaller than 10 mm 3 .

10. The device according to claim 9 , wherein the device is smaller than 1 mm 3 .

11. The device according to claim 1 , wherein the first and second materials are electrode layers positioned on opposing sides of the support.

12. An ingestible composition comprising:

(a) a device comprising:

(i) a support;

(ii) circuitry associated with the support;

(iii) a first material electrically coupled to the circuitry; and

(iv) a second material electrically coupled to the circuitry, wherein the first material is electrically isolated from the second material, wherein the first and second materials are selected to provide a voltage potential difference when in contact with an electrically conductive fluid, and wherein the circuitry is configured to modulate current flow through the electrically conductive fluid to generate an encoded monophasic signal which is conductively transmitted to a remote receiver; and

wherein the circuitry comprises a switch; and

wherein the circuitry is configured such that when the switch is closed, a current is produced between the first material and the second material; and

(b) a pharmaceutically acceptable carrier.

13. The composition according to claim 12 , wherein at least one of the first material and the second material are configured to be consumed and dissolved by the electrically conductive fluid.

14. The composition according to claim 12 , wherein the first material comprises a metal is selected from the group consisting of magnesium, zinc, sodium, lithium and iron.

15. The composition according to claim 14 , wherein the first material is doped with a non-metal.

16. The composition according to claim 12 , wherein the second material is a salt.

17. The composition according to claim 16 , wherein the salt is selected from the group consisting of copper salts and iron salts.

18. The composition according to claim 13 , wherein the first material is a metal and the second material is a salt.

19. The composition according to claim 13 , wherein the composition further comprises an active agent.

20. A method of producing and ingestible device comprising:

associating circuitry with a support;

associating a first material with the support, wherein the first material is electrically coupled to the circuitry; and

associating a second material with the support, wherein the second material is electrically coupled to the circuitry, wherein the first material is electrically isolated from the second material, wherein the first and second materials are selected to provide a voltage potential difference when in contact with an electrically conductive fluid, and wherein the circuitry is configured to modulate current flow through the electrically conductive fluid to generate an encoded signal which is conductively transmitted to a remote receiver; and

wherein the circuitry comprises a switch; and

wherein the circuitry is configured such that when the switch is closed, a current is produced between the first material and the second material.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2021
From: PROTEUS DIGITAL HEALTH, INC.
To: OTSUKA AMERICA PHARMACEUTICAL, INC.
Reel/Frame 056467/0595 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2021
From: OTSUKA AMERICA PHARMACEUTICAL, INC.
To: OTSUKA PHARMACEUTICAL CO., LTD.
Reel/Frame 056468/0329 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 14, 2015
From: HAFEZI, HOOMAN
To: PROTEUS DIGITAL HEALTH, INC.
Reel/Frame 036081/0336 →
CHANGE OF NAME Recorded Nov 2, 2012
From: PROTEUS BIOMEDICAL, INC.
To: PROTEUS DIGITAL HEALTH, INC.
Reel/Frame 029228/0436 →